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Abstract
Background: To examine adiponectin levels in people with Latent Autoimmune Diabetes in Adults using a
matched pair case control study.
Findings: Patients with LADA (n = 64), were matched for sex with type 2 diabetic and non-diabetic controls.
A matched paired T-test was used to examine average adiponectin levels in the LADA patients’ versus controls.
The average adiponectin level for the LADA patients was 9.96 μg/ml compared to 6.4 μg/ml for Type 2 matched
controls and 9.6 μg/ml for non-diabetic controls. Mean difference for the LADA-type 2 comparison was calculated
after data was log transformed and showed a difference of 1.58 μg/ml (95%CI: 1.28-1.95, p = 0.0001). There was no
significant difference between LADA and non-diabetic controls (p = 0.54).
Conclusions: Adiponectin levels are higher among people with LADA compared to those with type 2 diabetes
and are equivalent to levels seen in non-diabetic controls. This suggests that risk of complications in LADA, as with
type 1 diabetes may be related more to glycaemic control rather than to factors of the metabolic syndrome.
Background
Adiponectin is a marker of insulin resistance, with lower
levels being associated with reduced insulin sensitivity,
less favourable lipid profiles and increased risk of devel-
oping cardiovascular disease in many studies [1-4].
However this may not be so clear cut as more recent
studies in coronary patients have yielded contradictory
results [5]. Furthermore, adiponectin levels are lower in
people with type 2 diabetes and the metabolic syndrome
[6]. However, adiponectin levels have been found to be
elevated in people with a type 1 diabetes [7] and may be
associated with increased onset of microalbuminuria [8].
Latent autoimmune diabetes in adults [LADA] is a
slowly progressive type 1 diabetes [9-12] with features of
both type 1 and type 2 diabetes. A person with LADA is
n o ti n s u l i nd e p e n d e n ta td i a g n o s i sa n di nt h i sw a y
resembles type 2 diabetes. LADA can be distinguished
from type 2 diabetes by antibody test such as a glutamic
acid decarboxylase antibody (GADA) test. There is very
limited information available regarding the risk of heart
disease among people with LADA and existing data is
contradictory [13-15]. Adiponectin levels are a reflection
of the amount of visceral fat or the obesity levels of the
person. Thus, adiponectin levels may give an indication
of the extent to which abdominal obesity may play a
role in risk of complications for LADA patients. This
study aims to examine Adiponectin levels in people with
LADA compared to those with type 2 diabetes and com-
pared to non-diabetic controls.
Methods
Design
Matched case control study with cases (LADA patients)
matched with controls (type 2 diabetes and non-diabetic
controls) for sex as adiponectin levels are higher in
women compared to men [16]. The cases were matched
one to one with a type 2 diabetes control and a non-
diabetic control. Cases were not matched for BMI, as
obesity was not believed to be a confounder but to be a
causal factor [17].
Patients
1,630 patients over the age of 18, with a diagnosis of
type 2 diabetes within the previous 12 months (not requir-
ing insulin at diagnosis) were tested for GADA within the
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of 20 WHO units (27 Female, 37 Male) or more, were
recorded as GADA positive and labelled as LADA cases.
Those patients had a GADA test of 5 WHO units or less
were recorded as GADA negative and labelled as type 2
control patients. Those with GADA titres between 5 and
20 WHO units were excluded from the study.
Sex matched controls (n = 64) were selected at ran-
dom from the GADA negative type 2 patients. In addi-
tion, sex matched anonymised blood samples were
obtained from people who did not have a diagnosis of
diabetes on their medical record (non-diabetic controls
( n=6 4 ) )a n dh a dab l o o dt e s tw h i c hh a dan e g a t i v e
result were selected from normal blood samples going
through the Biochemistry Department of the ABM Uni-
versity NHS Trust.
Setting
GADA testing was conducted in May 2006 to Dec 2008.
Patients were tested by their general practitioner (GP) at
t h es a m et i m ea su n d e r g o i n gt heir first diabetes annual
review (DAR) blood tests.
Adiponection
The concentration of plasma adiponectin was assayed
using an ELISA-based Quantikine Human Acrp30 immu-
noassay kit (R&D Systems, Minneapolis, Minnesota)
according to the manufacturer’s instructions. The assay
measures total (low, middle and high molecular weight)
adiponectin and employs a quantitative sandwich enzyme
immunoassay technique to determine adiponectin con-
centrations. Standards over the range of 1-250 mg/L
were prepared using recombinant human adiponectin.
All plasma samples were diluted according to the manu-
facturer’s instructions. The intra-and inter-assay coeffi-
cients of variation are 5.83% and 3.12% respectively.
GADA antibody testing
GADA were measured using an ELISA (65 kDa anti-
body) from RSR Cardiff, UK [18] and analysed in the
Department of Immunology at Singleton Hospital,
Abertawe Bromorganwwg University NHS Trust. This
ELISA kit achieved 98% (n = 100) specificity and 92%
(n = 50) sensitivity in the Diabetes Antibody Standardi-
zation Programme (DASP) [19].
Statistical analysis
The Shapiro-Wilk test was used to test for normal dis-
tribution. The data were log transformed and matched
pair T-tests were used to compare LADA patients with
type 2 diabetic controls and with non-diabetic controls.
SPSS version 13 was used for analysis.
Ethical approval was granted by the South West Wales
REC in October 2008.
Results
The clinical characteristics and demographics of LADA
patients and the non matched type 2 control patients are
outlined in a previous study [20] (see table 1). However, as
the non diabetic control group did not give informed con-
sent we had very limited information regarding their clini-
cal characteristics. When matched the average age of
participants was 53 years (S.D. 15.6 yrs), 54 years (S.D. 20
yrs), and 54 years (S.D. 14.6 yrs) for the LADA, non-
diabetic and type 2 diabetes controls respectively.
Patients with LADA (GAD antibody positive) had
higher adiponectin levels than those with type 2 diabetes
(GAD antibody negative) (Table 2). However, adiponec-
tin levels for LADA patients did not differ from those
found in non-diabetic controls.
Discussion
Patients with LADA have higher adiponectin levels than
matched subjects with type 2 diabetes. This would suggest
that abdominal obesity and visceral fat is less likely to be a
risk factor or a causal factor for LADA. It is known that
the BMI is lower among those with LADA compared with
type 2 diabetes [20]. However, this study suggests that
people with LADA are leaner for both abdominal/visceral
fat as well as for subcutaneous/peripheral fat.
Table 1 Demographic characteristics
LADA Type 2
diabetes
Mean difference
(95% CI)
Age (years) 49.6 ± 15.3 57.0 ± 14.8 7.4 (4.9-9.8)
BMI (kg/m
2) 28.3 ± 5.7 31.3 ± 6.4 3.0 (1.9-4.0)
Table 2 Adiponection in LADA Cases and the Controls
LADA
case
(n = 64)
Type 2 control
(n = 64)
Non-diabetic control
(n = 64)
Mean difference LADA-Type
2 controls
Mean difference LADA-
Nondiabetic controls
Adiponectin
(S.D)
9.96 (6.1) 6.46 (5.0) 9.60 (6.3) 3.49 (95%CI: 1.7-5.3) 0.35 (95%CI: -1.8 to 2.5)
Log transformed
data
0.919
(0.266)
0.717 (0.27) 0.892 (0.29) 0.20 (0.11-0.29) p = 0.0001 0.027 (-0.06 to 0.11) p = 0.54
S.D-Standard Deviation.
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T h i ss t u d yc o n f i r m sf i n d i n g sf r o mo t h e rp r e v i o u s
research [21] that the metabolic syndrome may not be a
characteristic of LADA. It is possible that glycaemic
control may be more of a risk factor for complications
in LADA in the same way as classical Type 1 diabetes
[15]. A prospective study with baseline adiponectin mea-
surements is required within a sample of subjects with
LADA to examine this further.
List of abbreviations
LADA-latent autoimmune diabetes in adults, GADA-glutamic acid
decarboxylase antibody, BMI-Body Mass Index.
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